Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Pinpoint Genomics releases Pinpoint Dx Lung Assay
The assay is a molecular diagnostic assay that differentiates between patients at high, intermediate or low risk of early death after surgery to remove a non-squamous, non-small cell
The assay is a molecular diagnostic assay that differentiates between patients at high, intermediate or low risk of early death after surgery to remove a non-squamous, non-small cell
Orteronel, discovered by Takeda, is an oral, non-steroidal androgen synthesis inhibitor that has been shown in pre-clinical studies to selectively inhibit the 17, 20 lyase enzymes which help
Bydureon is a glucagon-like peptide-1 (GLP-1) receptor agonist indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes in multiple
The primary endpoint of the Phase 2 study is overall survival. A preliminary analysis of data from the study showed a difference in survival favoring the placebo plus
Bosutinib is an oral, once-daily, investigational dual Src and Abl kinase inhibitor with minimal inhibitory activity against c-kit and PDGFR. By dual inhibition of the Src and Abl
Under the term sheet for the co-promotion and sale agreement, Apricus will receive rights to co-promote Granisol and AQUORAL in the US, with exclusive promotion rights in certain
As per the extension, Novartis will fund research at GenVec through January 2013 to support its hearing loss and balance disorders program. GenVec has entered into a worldwide
INLYTA is an oral therapy designed to selectively inhibit vascular endothelial growth factor receptors 1, 2 and 3, which can influence tumor growth, vascular angiogenesis and progression of
Xiaflex (collagenase clostridium histolyticum) is a biologic for the treatment of adult Dupuytren’s contracture patients with a palpable cord. Xiaflex treatment is intended to target and lyse, or
Tasimelteon is a circadian regulator in development for the treatment of Non-24-Hour Disorder in totally blind individuals with no light perception. This observation was made in four patients